相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Alvaro Moreira et al.
IMMUNOTHERAPY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
Michael R. Cassidy et al.
EBIOMEDICINE (2017)
Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity
Yi Ban et al.
CANCER RESEARCH (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Prognostic score for patients with advanced melanoma treated with ipilimumab
Stefan Diem et al.
EUROPEAN JOURNAL OF CANCER (2015)
Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells
Rafael Carretero et al.
NATURE IMMUNOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
J. Delyon et al.
ANNALS OF ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance
Ljubov Simson et al.
JOURNAL OF IMMUNOLOGY (2007)
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent
SH Jaber et al.
ARCHIVES OF DERMATOLOGY (2006)
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model
H Schmidt et al.
BRITISH JOURNAL OF CANCER (2005)
分享论文
